Volume 35, 5 November 2004 11/2004
 
  SPOT ON

MSD: dangers of rofecoxib concealed for years

 
  THERAPIES FROM A CRITICAL VIEW POINT
 

Clopidogrel (ISCOVER, PLAVIX): how long after angioplasty?
Slow-release nifedipine for angina pectoris?

 
  NEW ON THE MARKET
 

Labelling of new drugs in the a-t
Duloxetine (YENTREVE) for urinary stress incontinence

 
  REVIEW
 

How far is influenza vaccination evidence-based?

 
  a-t READERS' QUESTIONS AND COMMENTS
 

Is WICK ERSTE ABWEHR effective?
Insulin glargine (LANTUS): worsening of retinopathies?

 
  IN BRIEF
 

USA: No licence for Ximelagatran (EXANTA)
Glucocorticoids increase mortality in severe head injury
Lactobacillus does not prevent post-antibiotic vulvovaginal candidiasis
Once again: quality problems of drugs used in traditional Chinese medicine (TCM)

 
  CURRENT ADR NETWORK REPORT
 

Hair loss after hexavalent vaccine (HEXAVAC)
Addendum: double reporting of a tolperisone-induced drug reaction (MYDOCALM)

 
  SIDE EFFECTS
 

Cox-2-inhibitors and cardiovascular toxicity

 
  DOCUMENTATION
 

Rise and fall of rofecoxib (VIOXX)

 
© arznei-telegramm 11/2004